May FDA Enforcement Actions: What Food & Beverage Startups Need to Know

Every month, the FDA takes enforcement action against companies that violate food and supplement regulations. May's enforcement round-up reveals critical compliance gaps that could derail your startup. Here's what happened and what you need to do differently.

The FDA issued dozens of warning letters and import detention actions in May, targeting preventable compliance failures across food, beverage, and dietary supplement companies. These enforcement actions weren't directed at innovative startups pushing boundaries—they targeted businesses that missed foundational regulatory requirements. Understanding May's FDA enforcement actions patterns helps you avoid becoming a cautionary tale and keeps your startup focused on sustainable growth.

Overview of May's FDA Enforcement Actions

May's enforcement activity reflected ongoing FDA priorities: misbranded products, inadequate manufacturing controls, and undeclared allergens. The FDA issued warning letters to manufacturers across the United States, Canada, and India, with particular focus on dietary supplement companies making unauthorized health claims. Import detention actions concentrated on botanical ingredients from China and India lacking proper documentation or showing contamination risks. These actions weren't random—they targeted systemic gaps in preventive controls, labeling accuracy, and supply chain documentation that startups often overlook during rapid scaling.

Warning Letters: Breaking Down Key Violations

The most common violations involved misbranded product claims—specifically, health statements that crossed the line from permissible structure-function claims into unapproved drug territory. Under the FD&C Act Section 201(n), any claim suggesting a product treats, prevents, or cures disease constitutes misbranding. May's warning letters repeatedly cited supplements marketed for "immune support" that actually claimed disease prevention, beverages labeled with cardiovascular benefits unsupported by evidence, and probiotic products making clinical claims without substantiation. Current Good Manufacturing Practice deficiencies under 21 CFR 117 also dominated enforcement actions, with inadequate preventive controls for allergen management and environmental monitoring failures cited repeatedly across food facilities.

Import Alerts and Detention Without Physical Examination (DWPE)

The FDA maintains import alerts when products from specific suppliers or countries pose recurring safety risks. May's detentions included botanical ingredients from multiple suppliers in Asia lacking proper testing documentation, seafood products with undeclared processing allergens, and supplement raw materials showing heavy metal contamination. Companies seeking to regain FDA approval for detained imports must provide comprehensive testing data, manufacturing facility inspections, or supplier certifications. This process requires 30-90 days and significant documentation investment. Startups relying on single-source imports face serious supply chain disruption—diversifying suppliers and maintaining supplier qualification files prevents these delays.

Supplement-Specific Enforcement Trends

Dietary supplement companies faced heightened scrutiny in May, particularly those making unapproved health claims targeting medical conditions. The FDA found numerous supplements marketed for diabetes management, anxiety relief, and arthritis treatment—claims that transform supplements into unapproved drugs. Adulteration with undisclosed pharmaceutical ingredients represented the second major category of violations. Several companies added prescription-strength ingredients to weight-loss supplements without disclosure, creating serious safety and liability exposure. Structure-function claims under FDA guidance must describe normal function support only—"supports healthy blood sugar" passes review, but "manages diabetes" triggers enforcement. Supplement CGMP requirements under 21 CFR 111 require documentation of ingredient verification, batch testing, and quality assurance that many startups underestimate.

Beverage Industry Enforcement Focus

Beverage enforcement actions centered on three areas: inadequate caffeine labeling, allergen declaration failures, and unauthorized ingredient usage. Energy drinks and enhanced beverages often failed to declare total caffeine content from all sources—both added caffeine and naturally-derived sources must be included. May's actions also cited multiple beverage products containing undeclared allergens like sesame, tree nuts, or milk derivatives from flavorings or processing aids. Some companies used ingredients not listed on the FDA's Generally Recognized as Safe (GRAS) list without proper safety substantiation. Accurate labeling under 21 CFR 101.4 for allergens and transparent ingredient sourcing protect both consumer safety and your startup's reputation.

How to Conduct Your Own Compliance Audit

Start by reviewing every label claim against current FDA guidance documents—compare your product language to compliant competitor labels and FDA warning letter databases. Document the scientific substantiation behind each claim, noting which claims need removal or revision. Audit your manufacturing facility's preventive controls documentation: Do you have written procedures for allergen segregation? Can you trace ingredients back to verified suppliers? Review your CGMP implementation across production, testing, and quality assurance. For supplements, verify that your contract manufacturer holds current 21 CFR 111 certification. Create an allergen management matrix identifying all allergens in your facility and procedures preventing cross-contamination. This self-audit costs time now but prevents costly enforcement responses later.

What to Do If You Receive an FDA Warning Letter

You typically have 15 business days to acknowledge receipt of a warning letter. Your response requires detailed corrective actions addressing each cited violation, implementation timelines, and preventive measures preventing recurrence. Responses should reference specific regulatory citations and demonstrate understanding of violations—vague commitments to "improve practices" won't satisfy FDA concerns. Many startups benefit from engaging regulatory counsel at this stage, especially if violations involve complex manufacturing changes or claims substantiation. The FDA expects concrete evidence of compliance within the timeframe stated in your response. Follow-up inspections verify that promised corrections actually occurred. Documentation of corrective actions—facility upgrades, retrained staff, revised procedures—demonstrates good faith compliance commitment.

Key Takeaways for Startups

• Preventive compliance costs significantly less than corrective enforcement responses, facility modifications, or product recalls.

• Claims substantiation must happen before product launch—retroactive research and label corrections damage trust and invite enforcement attention.

• Labeling accuracy, particularly for allergens and health claims, represents your startup's regulatory foundation and consumer safety responsibility.

• Import screening and supplier qualification prevent supply chain disruptions that can halt production and revenue growth.

• Structure-function claims require careful language distinction from disease claims—single word choices determine regulatory classification.

May's FDA enforcement actions demonstrate that startup growth and regulatory compliance move together, not separately. The companies cited in enforcement actions weren't necessarily bad actors—they were founders who prioritized speed over documentation, assumed their manufacturing partner handled compliance details, or didn't realize that supplement claim language carries drug-level regulatory weight. These are correctable mistakes when caught early.

Your startup succeeds by building compliance into every process from ingredient sourcing through labeling approval. Review your products against May's enforcement patterns, strengthen your preventive controls documentation, and audit your claims against FDA guidance. The regulatory landscape isn't punitive—it's predictable. Companies that understand FDA enforcement actions requirements and implement them systematically protect their consumers, their business, and their growth trajectory.

Don't let your startup become next month's enforcement round-up. Download our FDA Compliance Checklist for startups or schedule a consultation with our regulatory experts to audit your products, claims, and processes today. Your compliance foundation determines your success.